Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature.

Florence, Schleich;Elleni-Sofia, Vaia;Pilette, Charles;Vandenplas, Olivier;Olivier, Michel;et.al.
(2020) The journal of allergy and clinical immunology. In practice — Vol. 8, n° 7, p. 2412-2413 (2020)

Files

SchleichFJAllergyClinImmunolPract2020.pdf
  • Open Access
  • Adobe PDF
  • 107.2 KB
Download

Details

Authors
Show more
Abstract
(en) Our data provide further evidence supporting the effectiveness of mepolizumab in allergic bronchopulmonary aspergillosis because it decreases the dose of oral corticosteroids and the rate of exacerbations, and improves asthma control and quality of life.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Florence, S., Elleni-Sofia, V., Pilette, C., Vandenplas, O., Jean-Luc, H., Alain, M., Rudy, P., Shane, H., Renaud, L., & Olivier, M. (2020). Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature. The journal of allergy and clinical immunology. In practice, 8(7), 2412-2413. https://doi.org/10.1016/j.jaip.2020.03.023 (Original work published 2020)